Author

S. Shah

Observed names: Syed R. Shah, Syed Shahzad Hussain Shah

Institution: Punjab Institute of Neurosciences

Observed institutions: Translational Genomics Research Institute, Mayo Clinic, University of Arizona, HonorHealth, Pharmacyclics (United States), Punjab Institute of Neurosciences, University of Rochester, All India Institute of Medical Sciences

ORCID: 0000-0003-2344-4774

Observed ORCID: 0000-0003-2344-4774

OpenAlex ID: A5109340004

Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma

2016 · Hani M. Babiker, Irbaz B. Riaz, et al. · Anti-Cancer Drugs · 5

Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor in patients with advanced pancreatic cancer receiving treatment with gemcitabine.

2011 · R. K. Ramanathan, V. Gressler, et al. · Journal of Clinical Oncology · 3

Phase I/II pharmacokinetic and pharmacodynamic study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor, in patients with advanced pancreatic cancer receiving treatment with gemcitabine.

2011 · R. K. Ramanathan, M. Chadha, et al. · Journal of Clinical Oncology · 2

Abstract 251: Hypophosphatemia in Critically Ill Children

2014 · R. Lodha, S. Shah, et al. · Pediatric Critical Care Medicine · 1

Primary intracranial rhabdomyosarcoma: A systematic review of existing literature from 2000 to 2024

2025 · Haseeb Mehmood Qadri, Momina Khawaja, et al. · Pakistan Journal of Medical Sciences

507TiP PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer

2021 · J.M. Hubbard, M. Aapro, et al. · Annals of Oncology

Works count: 6

Citation count: 11

H-index: 2

I10-index: